…………………. catching up on recent FDA approvals The FDA recently approved a new infused therapy, Bizengri (zenocutuzumab-zbco) from Merus N.V., indicated for adults with pancreatic adenocarcinoma
The FDA recently approved a biosimilar, Yesintek (Ustekinumab-kfce) from Biocon Biologics Ltd, as a biosimilar to the reference product, Stelara (Ustekinumab). This approval is the
……….. catching upon FDA approvals The FDA recently approved a new ORAL specialty therapy, Revuforj (revumenib) from Syndax Pharmaceuticals, for the treatment of relapsed or
………… catching up on FDA approvals The FDA recently approved a new infused therapy, Aucatzyl (obecabtagene autoleucel) from Autolus Inc., indicated for the treatment of adults
The NHIA recently released a comprehensive list of therapies that have been routinely dispensed by home infusion providers. This comprehensive grouping, especially by therapeutic category and
The FDA recently approved a new infused therapy, Vyloy (zolbetuximab-clzb) – in combination with fluoropyrimidine and platinum-containing chemotherapy – from Astellas Pharma Inc., for the
So, how much do you know about bispecific therapy? Can you even offer a passing definition? Well, read on dear reader….. and learn enough to
This new year should be verrrrry interesting…… especially with respect to the FDA and a host of changes that are likely to be implemented in the agency. One
The year 2024 was a very busy year for specialty pharmacy. So many SP therapies were approved by the FDA that we are still catching
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases
